Saturday, July 14, 2018 3:20:19 AM
From the website that markets "TraumaGel"...…..
<<<<<<<<<<<<<TRAUMAGEL™ is a hemostatic device with a prospective indication for temporary use to control external traumatic bleeding not amenable to tourniquet application.
Intended applications of TRAUMAGEL™ include military combat use and civilian emergency medical services use. TRAUMAGEL™ is currently undergoing exploratory proof of concept testing by Cresilon.
For demonstration purposes only. TRAUMAGEL™ is a hemostatic device under investigation by Cresilon for use in humans. It is not FDA approved or CE marked at this time.>>>>>>>>>>>>>>>>>>>>>>>>
This 17 year old who is now in his 20's (or maybe a grand-dad by now) was able to bring to market a product to use on animals.
And I don't know how much you know about science.....but.....
that ain't nothing compared to getting something approved for use with humans. Animal testing is still legal for the most part.
And look at their own website. Not even an FDA approval for an external human product...……
Much less the internal one Arch has developed...and the numerous others.
This 17 year old is running a popsicle stand - selling lemonade....
compared to Arch...……………..
No comparison...….
I suggest people do their homework...….
It is like comparing Lennon and McCartney from the Beatles to the local hacker down the road in the cover band that plays bars on the weekends...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM